一 | Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are weaker than it had expected and cut revenue projections by $9 billion for the year. Falling sales of both clipped sales in the second quarter, but Pfizer said in August that it expected a rebound in the second half of 2023. Shares of Pfizer slipped more than 1% before the opening bell Monday and Moderna, which is heavily reliant on the competing vaccine it makes, slid nearly 5%. Pfizer said Friday that global usage of Paxlovid is trending slightly above last year, but that it's still below expectations.The fall vaccination period just began and the New York City drugmaker said that it's too soon to get a handle on vaccination rates for the year.Full-year revenue for Paxlovid and Comirnaty is expected to be approximately $12.5 billion, short $9 billion of what it had expected. Pfizer is lowering its full-year revenue expectations for Paxlovid by approximately $7 billion. That number also accounts for delayed commercialization of the product, which was pushed to January 2024 from the company's previous expectation of commercialization in the second half of this year. Pfizer is also lowering its 2023 revenue expectations for Comirnaty by approximately $2 billion due to lower-than-expected vaccination rates.Pfizer Inc. now foresees 2023 revenue in a range of $58 billion to $61 billion, down from its prior forecast for $67 billion to $70 billion. It now projects full-year adjusted earnings between $1.45 and $1.65 per share due to lower-than-anticipated revenue for COVID-19-related products and inventory write-offs.That is short of the full-year revenue of $63.61 billion and earnings of $2.77 per share that Wall Street was expecting, and far short of the company's previous projections of per-share earning between $3.25 and $3.45. JPMorgan said the company's update solves an ongoing U.S. Paxlovid inventory debate and it anticipates the company's bigger-than-expected cuts to its sales projections will help put a floor under per-share earnings expectations for next year.。
IT之家获悉，目前宁德时代商城已上架三类储能产品。电芯方面，在售 280Ah（1P）、314Ah 两款主流磷酸铁锂储能电芯，587Ah 电芯、储能电箱（280Ah 及 314Ah-长款）和储能集装箱（EnerD 及 EnerD+）已同步上架展示，正式开售时间待定，电芯最低 3 箱起订。
据悉，平台常备现货库存，付款后在 3-5 天发货。小批量采购同样可享大客户级别的 5 年质保服务，同时享有首单立减 2% 的优惠。
二 | 目前，飞毛腿、快卜等储能集成商已率先采购。另据新浪科技报道，官方“宁德时代储能”微信公众号及视频号也已同步启动，未来官方计划围绕储能电池及设备开展直播销售。
Current article:http://lh8xd.wairanleichengwochengzhui.shop/t46v5/gso5tiw.html
Published on:06:50:54